Japan Urges Fishermen to Avoid Senkaku Islands as China Tensions Rise 
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
U.S. and El Salvador Sign Landmark Critical Minerals Agreement to Boost Investment and Trade 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
U.S. Government Enters Brief Shutdown as Congress Delays Funding Deal 
ICE Blocked From Entering Ecuador Consulate in Minneapolis During Immigration Operation 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
U.S.–Venezuela Relations Show Signs of Thaw as Top Envoy Visits Caracas 
Trump Nominates Brett Matsumoto as Next Bureau of Labor Statistics Commissioner 
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
Syria-Kurdish Ceasefire Marks Historic Step Toward National Unity 
Trump Pushes Back on 401(k) Homebuyer Plan Amid Housing Affordability Debate 
Kevin Warsh’s Fed Nomination Raises Questions Over Corporate Ties and U.S.–South Korea Trade Tensions 
A bipartisan group of U.S. lawmakers has urged the Biden administration to consider restricting biotechnology exports to China’s military, citing concerns over potential weaponization to create toxic pathogens. In a letter to Commerce Secretary Gina Raimondo, lawmakers, led by Republican China Select Committee Chairman John Moolenaar and Democrat Raja Krishnamoorthi, called for licensing restrictions on U.S. pharmaceutical companies collaborating with Chinese military-owned medical entities.
The letter, reported by Reuters, highlights the national security risks of U.S.-China biotech competition, emphasizing the potential threat to healthcare advancements and American medical data security. Chinese Embassy spokesperson Liu Pengyu dismissed the claims as "malicious speculation," reiterating Beijing’s opposition to biological weapons.
Concerns about China’s biotechnology activities have grown among U.S. officials. In August, lawmakers, including Democrat Anna Eshoo, urged the FDA to increase scrutiny of U.S. clinical trials in China, citing risks of intellectual property theft and forced participation of Uyghurs in Xinjiang. U.S. pharmaceutical companies have reportedly collaborated with Chinese military-run hospitals on hundreds of clinical trials in the past decade.
In a January response, FDA Acting Associate Commissioner Laura Paulos assured lawmakers of strict protections for trial participants, stating that legally effective, informed consent is required. On intellectual property theft concerns, she deferred the matter to other federal agencies.
Commerce Secretary Raimondo’s upcoming departure could limit immediate action on new controls. However, the letter underscores growing bipartisan concern over China’s role in biotechnology and its implications for global security.
This development reflects broader efforts to address the strategic challenges posed by China across various industries, including biotechnology and healthcare.
